Literature DB >> 16722970

Use of antiepileptic drugs in Estonia: an epidemiologic study of adult epilepsy.

A Oun1, S Haldre, M Mägi.   

Abstract

An evaluation of general antiepileptic treatment patterns and utilization of particular drugs was carried out based on the prevalence study of adult active epilepsy in a sample of the Estonian population. The antiepileptic drugs (AEDs) used, and their doses were recorded and compared with clinical characteristics. Nineteen per cent of the subjects did not take any AED on the prevalence day; 83% of those on medication were taking a single drug, 15% two, and 2% three AEDs. Localization-related symptomatic epilepsies were most frequently treated with AEDs and were also the largest group receiving polytherapy. The most common agent was carbamazepine (68%), followed by barbiturates. Valproate and phenytoin were used much less. The study design and its impact on the interpretation of results is discussed. The percentage of sodium-channel blockers is generally comparable with that reported from other European countries. The small share of valproate is probably a result of the extensive utilization of barbiturates, and is partially related to the age distribution in the study. The high figure of AED-free cases, and small percentage of polytherapy indicates a tendency for undertreatment. Some points for improvement in AED therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722970     DOI: 10.1111/j.1468-1331.2006.01268.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

1.  Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.

Authors:  Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Nobuyuki Mishima; Yoshiyuki Kagawa; Yushi Inoue
Journal:  Eur J Clin Pharmacol       Date:  2015-09-22       Impact factor: 2.953

2.  Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011.

Authors:  Domenico Italiano; Annalisa Capuano; Angela Alibrandi; Rosarita Ferrara; Angelo Cannata; Gianluca Trifirò; Janet Sultana; Carmen Ferrajolo; Michele Tari; Daniele Ugo Tari; Margherita Perrotta; Claudia Pagliaro; Concita Rafaniello; Edoardo Spina; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

3.  Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07.

Authors:  Alessandro Oteri; Gianluca Trifirò; Maria Silvia Gagliostro; Daniele Ugo Tari; Salvatore Moretti; Placido Bramanti; Edoardo Spina; Achille Patrizio Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

4.  Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults.

Authors:  Hajo M Hamer; Richard Dodel; Adam Strzelczyk; Monika Balzer-Geldsetzer; Jens-Peter Reese; Oliver Schöffski; Wolfgang Graf; Stefan Schwab; Susanne Knake; Wolfgang H Oertel; Felix Rosenow; Karel Kostev
Journal:  J Neurol       Date:  2012-04-28       Impact factor: 4.849

5.  Changes in the Peripheral Blood Gene Expression Profile Induced by 3 Months of Valproate Treatment in Patients with Newly Diagnosed Epilepsy.

Authors:  Aleksei Rakitin; Sulev Kõks; Ene Reimann; Ele Prans; Sulev Haldre
Journal:  Front Neurol       Date:  2015-08-31       Impact factor: 4.003

6.  Sociodemographic, Rationale Drug Use of Antiepileptic Drugs among Pediatric Patients with Epilepsy: A Prospective Study at a Tertiary Care Hospital.

Authors:  S Dwajani; E Adarsh; K S Nirmala; H Sahajananda
Journal:  J Neurosci Rural Pract       Date:  2019-10-09

7.  Educational inequalities in epilepsy mortality in the Baltic countries and Finland in 2000-2015.

Authors:  Andrew Stickley; Aidan Neligan; Aleksei Baburin; Domantas Jasilionis; Juris Krumins; Pekka Martikainen; Naoki Kondo; Tomiki Sumiyoshi; Jae Il Shin; Hans Oh; Kyle Waldman; Mall Leinsalu
Journal:  Sci Rep       Date:  2022-03-17       Impact factor: 4.379

8.  Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia.

Authors:  Aleksei Rakitin; Triin Eglit; Sulev Kõks; Margus Lember; Sulev Haldre
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.